The global preclinical medical device testing services market size was valued at USD 5.7 billion in 2021 and is anticipated to exhibit a CAGR of 11.3% during the forecast period. The growing demand for technologically advanced medical devices is one of the key reasons driving the market. Apart from this, the strict regulations by the regulatory authorities to develop high-quality devices are further promoting the market. The COVID-19 pandemic had created an urgent need for medical devices owing to which several medical device companies around the globe developed new devices for testing COVID-19. This is likely to have a positive impact on the market.
The high prevalence of diseases is creating an interest among the manufacturers to develop new medical devices. Product design and development of medical devices is a complex procedure. The high complexities associated with medical device design and the growing prevalence of diseases are likely to increase the demand for preclinical medical device testing services.
Over the years, the technological advancements in medical devices have improved. Medical devices now are equipped with IoT and AI. Moreover, the market players are also keen on launching advanced medical devices to stay competitive in the market. For instance, in August 2021, PaxeraHealth, a provider of imagining heath announced that it is launching an AI-based imagining platform in the U.S. Such initiatives are further expected to enhance the demand for preclinical medical device testing services.
During the advent of the COVID-19 pandemic, the preclinical medical device trials were not focused on treating and diagnosing diseases like cancer, cardiovascular diseases, and other diseases owing to the widespread of COVID-19 globally. This had slowed down the market to some extent. The pandemic, however, had created an urgent demand for PPE kits, masks, IVD kits, and other devices so as to curb the spread of disease. The public organizations were also keen to support the development of medical devices for diagnosing and treating COVID-19. For instance, in April 2021 the NIH provided USD 443,000 funding to the Rutgers researchers to develop the COVID-19 Breathalyzer Test. Such initiatives are expected to have a positive impact on the market.
The microbiology & sterility testing segment accounted for the maximum revenue share of 34.2% in 2021. Microbiology & sterility testing is one of the major tests included in pre-clinical medical device testing. These tests help in detecting the presence of microorganisms in the device. The FDA and other regulatory bodies require these tests for validation purposes. These tests are also performed as a part of regular quality control. The growing demand for medical devices globally is driving the segment growth.
The chemistry test segment is expected to rise with the fastest CAGR of 11.7% over the forecast period. Chemical testing is done for characterizing, identifying, and comprehending the chemicals used for manufacturing medical devices. Chemical testing complies with the ISO 10993-17 and 10993-18T regulations. The complexities associated with the designing of medical devices are driving the segment growth.
North America held a substantial revenue share of 25.6% in 2021. The rise in the demand for advanced medical devices and the presence of sophisticated infrastructure for developing complex, highly reliable, and high-end medical devices is driving the preclinical medical device testing services market in the region. Moreover, the presence of key players operating in the market is further contributing to the growth of the North American market.
The Asia Pacific market is expected to rise with the fastest growth of 12.2% over the forecast period. The low cost associated with outsourcing medical device testing services in the Asia Pacific is one of the major factors driving the regional market. The growing demand for advanced medical devices in the region owing to the growing disease burden is further contributing to the regional market growth.
Expansions, acquisitions, and partnerships among others were the key strategies adopted by key players to maintain their market share. For instance, in December 2021, life sciences company LabCorp acquired Toxikon Corporation a preclinical contract research organization. This acquisition was intended to expand Labcorp’s nonclinical development testing capabilities for medical device, biotech, and pharmaceutical clients. Similarly, in November 2019, WuXiAppTec lab testing division expanded its toxicology facility in Suzhou China to provide full-service preclinical and clinical-stage toxicology. Some prominent players in the global preclinical medical device testing services market include:
SGS SA
Labcorp
Eurofins Scientific
Pace Analytical Services LLC
Intertek Group Plc
WUXI APPTEC
TÜV SÜD AG
Sterigenics International LLC
Nelson Labs
North American Science Associates, Inc.
Charles River Laboratories International, Inc.
Report Attribute |
Details |
Market Size value in 2022 |
USD 6.3 billion |
Revenue forecast in 2030 |
USD 14.9 billion |
Growth Rate |
CAGR 11.3% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD Million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Service, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Netherland; Belgium; Switzerland; Russia; Sweden India; Japan; China; Thailand; South Korea; Australia; Malaysia; Indonesia; Singapore; Philippines; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE; Israel; Egypt |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Key companies profiled |
SGS SA; Eurofins Scientific; Pace Analytical Services LLC; Intertek Group Plc; WUXI APPTEC; TÜV SÜD AG; Sterigenics International LLC; Nelson Labs; North American Science Associates, Inc.; Charles River Laboratories International, Inc |
15% free customization scope (equivalent to 5 analysts' working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Segments Covered in the Report
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global preclinical medical device testing services market report on the basis of service and region
Service Outlook (Revenue, USD Million, 2018 - 2030)
Biocompatibility Tests
Chemistry Test
Microbiology & Sterility Testing
Bioburden Determination
Pyrogen & Endotoxin Testing
Sterility Test And Validation
Antimicrobial Activity Testing
Others
Package Validation
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
France
Germany
U.K.
Italy
Spain
Netherlands
Belgium
Switzerland
Russia
Sweden
Asia Pacific
Japan
China
India
Australia
South Korea
Malaysia
Indonesia
Singapore
Philippines
Thailand
Latin America
Brazil
Mexico
Argentina
Colombia
Chile
Middle East & Africa
South Africa
Saudi Arabia
UAE
Israel
Egypt
b. The global preclinical medical device testing services market was estimated at USD 5.7 billion in 2021 and is expected to reach USD 6.3 billion by 2022.
b. The global preclinical medical device testing services market is expected to grow at a compound annual growth rate of 11.3% from 2022 to 2030 to reach USD 14.9 billion by 2030.
b. Microbiology and sterility testing services dominated the market with a share of 34.2% in 2021. This is due to the ability of these tests to determine the presence or absence of extraneous viable contaminating microorganisms in products designed for patients.
b. Some of the players operating in this market are SGS SA; Toxikon, Inc.; Eurofins Scientific; Pace Analytical Services, LLC; WuXi AppTec.; NORTH AMERICAN SCIENCE ASSOCIATES, INC.; Charles River Laboratories International, Inc. Key parameters affecting the competitive nature of the market include geographic expansion, collaboration, partnership, mergers and acquisition.
b. The preclinical medical device testing services market is expected to grow lucratively during the COVID-19 pandemic. The main drivers for this market are the emerging players operating in this industry over the past decade.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.